List of Drugs under Cancer Drugs Fund, South Central SHA A very informative list, for which many thanks to Clive South Central SHA Cancer Drugs Fund: Drugs & Indications of use in order of priority as advised to Clive Stone by Chief Executive on 8th November 2010 High Priority indications. In many cases already approved for funding through commissioners Drug | Indication | 5-Azacytidine | Intermediate 2 and high-risk myelodysplastic syndromes (MDS) | Bevacizumab | In combination with taxane-based chemotherapy for first-line chemotherapy of advanced breast cancer | Bexarotene | Cutaneous T-Cell lymphoma refractory to previous systemic treatment | Capecitabine | With mitomycin C and radiotherapy for Anal cancer | Cetuximab | Metastatic and/or recurrent squamous cell carcinoma of the head and neck | Cetuximab | Treatment of KRAS wild-type metastatic colorectal cancer, first line or recurrence | Docetaxel | With platinum +/- 5FU 1st line for upper GI –if there are cardiac contraindications to anthracyclines | Everolimus | 2nd line treatment of advanced renal cell carcinoma in patients whose disease has progressed on sunitinib | Gemcitabine | In combination with platinum for 2nd line or greater treatment of Hodgkin lymphoma in pts expected to have HSCT | Imatinib high dose | Metastatic exon 9 mutated GIST | Imatinib | Adjuvant treatment for patients at significant risk of relapse following resection of a gastrointestinal stromal tumour | Lapatinib | Breast cancer (for use in women with previously treated advanced or metastatic breast cancer) | Oxaliplatin | With Capecitabine and Epirubicin for 1st Line advanced oesophago-gastric cancer | Sorafenib | First line advanced hepatocellular carcinoma | Sunitinib | Treatment of advanced and/or metastatic pancreatic islet tumours (well differentiated PNETs) | Topotecan | Recurrent carcinoma of the cervix | Trastuzumab | As part of 1st-line combination chemotherapy for Her2 positive locally advanced or metastatic gastric cancer or cancer of the gastro-oesophageal junction |
Intermediate priority: recognised candidates for CDF support Drug | Indication | Bendamustine | First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate | Bendamustine | Indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen. | Bevacizumab | Second line metastatic Colorectal Cancer | Erlotinib | Monotherapy for maintenance treatment of NSCLC | Fulvestrant | 3rd or 4th line hormone antagonist therapy for locally advanced or metastatic Breast cancer | Lenalidomide | First relapse myeloma in patients where Bortezomib is contra-indicated | Pemetrexed | Second line Non Small Cell Lung Cancer | TCH 3/52 | Adjuvant high risk HER2+ve breast cancer in patients with second primary tumours | Y90 Ibritumomab Tiuxetan (Zevalin) | Patients with follicular lymphoma refractory to chemotherapy |
Low Priority for support Drug | Indication | Aflibercept | 3rd line treatment of ovarian cancer | Alemtuzumab | Relapsed, fludarabine refractory CLL | Arsenic Trioxide | 1st line consolidation therapy for adults with APML | Azacitidine | AML | Bevacizumab | In combination with oxaliplatin and 5FU or capecitabine for 1st line treatment of metastatic colorectal cancer | Bevacizumab | In combination with irinotecan for the treatment of patients with recurrent glioma | Bevacizumab | 1st line non-squamous NSCLC | Bortezomib | 2nd line or subsequent Waldenstrom's macroglobulinaemia (lymphoplasmacytic lymphoma) | Cabazitaxel | Secondline treatment of hormone-refractory prostate cancer following docetaxel-based therapy | Carboplatin + caelyx | Ovarian cancer 2nd line or greater | Clofarabine | Relapsed/refractory AML in elderly | Clofarabine with low dose cytarabine | 1st line AML in elderly patients (= 65 years old) with one or more of: adverse cytogentics; secondary AML; = 70 years old; significant co-morbidities; & not considered suitable for intensive chemotherapy | Dasatanib | Ph+ve ALL in those resistant to or intolerant to previous therapy | Decitabine | Myelodysplastic syndrome | Eribulin | 3rd line treatment of advanced or metastatic breast cancer | Erlotinib | 3rd line NSCLC for those who have entered a 2nd line trial | Everolimus | Treatment of pancreatic neuroendocrine tumours (pNETs) | Imatinib | ALL- relapsed/refractory Ph + | Ipilimumab | previously treated Unresectable stage III or IV malignant melanoma | Larotaxel | Advanced pancreatic cancer: recurrent and/or metastatic - second line | Lenalidomide | 2nd line or subsequent CLL | Nelarabine | T-ALL and T-LBL relapsed | Nilotinib (Tasigna) | 1st line chronic myeloid leukaemia | Ofatumumab | CLL resistant to Fludarabine and/or Alemtuzumab | Paclitaxel | 2nd line metastatic squamous cancer of anus | Panitumumab | Third line therapy of metastatic colorectal cancer | Pazopanib | 1st or 2nd line treatment of metastatic renal cell carcinoma | Pegylated Interferon | 2nd line Myeloproliferative neoplasms in patient unable to tolerate standard therapies - hydroxycarbamide, anagrelide or standard interferon | Pemetrexed | Maintenance treatment following first line chemotherapy for NSCLC | Picoplatin | 2nd line treatment of patients with platinum-refractory or -resistant SCLC | Rituximab | 1st line Low Grade CD20+ B-NHL eg Waldenstroms, marginal zone | Rituximab + any combination | Waldenstrom's macroglobulinaemia 2nd or subsequent line (lymphoplasmacytic lymphoma) | Sorafenib | First-Line Treatment of Patients With advanced NSCLC | Temozolamide | Metastatic melanoma with CNS involvement | Temsirolimus | Treatment of relapsed or refractory mantle cell lymphoma | Trabectedin | Treatment of relapsed ovarian cancer | Vinflunine | 2nd line advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regime |
Thought you may also like to see this link re Pazopanib (Votrient) an alternative drug for first line treatment: http://www.medicalnewstoday.com/articles/212472.php
NHS South Central Chief Executive Report July 2010 This is the first of my new style Chief Executive Report, which will be used to communicate key updates linked to the SHA’s six strategic priorities, as approved by the Board in May. A number of the commentaries below are supplemented by links which will take you to more detailed information for your consideration. Supporting implementation of national changes at the regional and local level |
1.1 The Publication of the White Paper The White Paper ‘Equity and excellence: Liberating the NHS”, published on 12 July 2010, sets out proposals for the future of the NHS. The vision is for the NHS to: Put patients at the heart of everything that we do - “No decision about me, without me” • Patients will be put at the heart of everything that we do: that means real choice about where and, in some cases, how they are treated • Patients given ability to access comprehensive information on many aspects of health allowing them to rate hospitals and clinicians according to the quality of care they provide • Patients given a stronger voice through the introduction of a new consumer champion, HealthWatch • Patients to benefit from better health outcomes through a relentless focus on continuously improving the clinical outcomes that really matter, not on inputs or processes Achieve outcomes that are among the best in the world •This is to be achieved by maintaining a clear focus on continuously improving clinical outcomes, rather than monitoring inputs or processes. • Targets without clinical justification will be removed - quality standards will become the foundation for commissioning care, payment systems, and inspection processes. • Our clinicians and scientists are as good as anywhere in the world and will help us to meet this challenge Empower clinicians to deliver results based on the needs of patients •Clinicians will be set free to make decisions about care based on patients’ needs and to achieve the best outcomes • A new independent NHS Commissioning Board will allocate and account for NHS resources, lead on quality improvement, and promote patient involvement and choice • NHS Trusts will become Foundation Trusts and be given more freedom • Monitor will be developed into an economic regulator and the Care Quality Commission will act as a quality inspectorate across health and social care 1.2 The Transition document Sir David Nicholson, NHS Chief Executive wrote to all Chief Executives on 13 July 2010 to set out how the community will lead the implementation of Liberating the NHS. He noted that as we move at pace to make the Government's vision a reality, it is vital to continue to deliver on quality, finance and performance, as well as make the required productivity savings of £15%u201020 billion. The letter provided a framework within which Strategic Health Authorities can lead this process regionally, and set out some initial actions that commissioners and providers need to take as part of the state of readiness for 2012. Andrea Young informed staff that the Executive Team will now discuss the plans in the document and progress the way forward for NHS South Central ensuring we continue to deliver for today whilst designing a new system for tomorrow. She emphasised the importance of caring for staff at this time and asked for staff involvement and participation as the new ways of working are embedded. 1.3 SHA Assurance 2010 The Department of Health's (DH) SHA Assurance review of SCSHA concluded on 15 and 16 July, with visits to most of the organisations in South Central, and the SHA itself. Initial feedback from the DH outlined a number of strengths in South Central's working arrangements: - strong PCTs, among the best in the country
- GP commissioners who were up for the challenge ahead
- strong and effective professional networks
- quality and safety being defining principles of how we all work
- good leadership development programmes
| 
